Japan Exchange
02:00:00 2024-04-26 am EDT
5-day change
1st Jan Change
1,512
JPY
0.00%
+4.13%
+7.65%
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024
August 03, 2023 at 02:00 am EDT
Santen Pharmaceutical Co., Ltd. provided dividend forecasts for the second quarter of 2024 and the fiscal year ending March 31, 2024. For the quarter, the company expects to pay a dividend of ¥16 against ¥16 paid last year.
Santen Pharmaceutical to Cancel 12 Million Treasury Shares
Mar. 25
MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024
Mar. 25
CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
Mar. 25
CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.
Mar. 21
CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months
Feb. 08
MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024
Feb. 08
CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy
Jan. 29
MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen
Jan. 07
MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
Jan. 05
CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares
Dec. 04
MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast
Nov. 08
MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
Nov. 07
CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024
Nov. 07
CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September
23-10-02
MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
23-10-02
CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy
23-09-21
MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
23-09-19
CI
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024
23-08-03
CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
23-08-03
CI
Santen Disposes of Shares as Restricted Stock-Linked Remuneration/Restricted Stock
23-07-24
MT
Visiox Pharma Enters into A Definitive Agreement with Santen Pharmaceutical Co., Ltd to License OMLONTI
23-07-19
CI
Bank Earnings Leave Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday
23-07-19
MT
Harrow Health Acquires Certain US, Canada Rights to Santen Pharmaceutical's Ophthalmic Portfolio
23-07-19
MT
Santen Pharmaceutical Co., Ltd. Signs Licensing Agreements
23-07-18
CI
Jefferies Adjusts Santen Pharmaceutical's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Buy
23-07-12
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
More about the company
Last Close Price
1,512
JPY
Average target price
1,767
JPY
Spread / Average Target
+16.83%
Consensus
1st Jan change
Capi.
+7.65% 3.5B +25.83% 661B +27.00% 566B -6.76% 352B +20.34% 332B +3.00% 283B +13.09% 231B +5.46% 200B -9.61% 195B -6.26% 145B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SANTEN PHARMACEUTICAL CO., LTD. 
